Lim, Y Y
Villemagne, V L
Laws, S M
Pietrzak, R H
Snyder, P J
Ames, D
Ellis, K A
Harrington, K
Rembach, A
Martins, R N
Rowe, C C
Masters, C L
Maruff, P
Article History
Received: 19 May 2014
Revised: 29 July 2014
Accepted: 21 August 2014
First Online: 7 October 2014
Competing interests
: CLM is an advisor to Prana Biotechnology Ltd and a consultant to Eli Lilly. RHP and PJS are scientific consultants to Cogstate Ltd. PM is a full-time employee of Cogstate Ltd. DA has served on scientific advisory boards for Novartis, Eli Lilly, Janssen and Pfizer Inc. RNM is a consultant to Alzhyme. CCR has served on scientific advisory boards for Bayer Pharma, Elan Corporation, GE Healthcare and AstraZeneca, has received speaker honoraria from Bayer Pharma and GE Healthcare and has received research support from Bayer Pharma, GE Healthcare, Piramal Lifesciences and Avid Radiopharmaceuticals. VLV served as a consultant for Bayer Pharma and has received research support from a NEDO grant from Japan. All other authors declare no conflict of interest.